1 / 7

Epidemiological Forecast of Myasthenia Gravis to 2024

"EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024" is now available at RnRMarketResearch.com Myasthenia gravis is an autoimmune disease that affects the nerves and muscles and is characterized by muscle weakness and fatigue.

Rudraksha123
Download Presentation

Epidemiological Forecast of Myasthenia Gravis to 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epidemiological Forecast of Myasthenia Gravis to 2024 By RnRMarketResearch Browse more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . This is a premium report price at US$3995 for a single user PDF license ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Epidemiological Forecast of Myasthenia Gravis to 2024 Myasthenia gravis is an autoimmune disease that affects the nerves and muscles and is characterized by muscle weakness and fatigue, especially weakness of the muscles controlling eye and eyelid movement, facial expression, chewing and talking. In some cases the muscles controlling breathing are also affected, which can lead to respiratory failure that requires intubation and mechanical ventilation, known as a myasthenic crisis. The muscle weakness seen in myasthenia gravis is most often caused by circulating antibodies that mistakenly attack healthy tissue and inhibit normal neuromuscular transmission by blocking or damaging muscle receptor cells. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Epidemiological Forecast of Myasthenia Gravis to 2024 GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of myasthenia gravis in the 7MM, from 106,845 cases in 2014 to 119,939 cases in 2024, at an Annual Growth Rate (AGR) of 1.23% in the forecast period. The highest number of diagnosed prevalent cases of myasthenia gravis fell into the =75 year age group in the 7MM. The majority of diagnosed prevalent cases of myasthenia gravis in the 7MM in 2014 were women. The US and the 5EU markets follow a similar pattern, in which Class III has the highest number of diagnosed prevalent cases. Japan, however, has more cases in Class II than any other Class. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Epidemiological Forecast of Myasthenia Gravis to 2024 To build the epidemiological forecast of myasthenia gravis in the 7MM, GlobalData epidemiologists reviewed the literature and obtained country-specific, population-based studies that reported myasthenia gravis prevalence as determined via medical record reviews. GlobalData epidemiologists obtained country-specific diagnosed prevalence data for the US, Italy, the UK, and Japan, thereby providing valuable analysis of epidemiological trends amongst the 7MM. This forecast also includes age- and sex-specific segmentations, thereby providing detailed information about the characteristic of the disease in each market. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Epidemiological Forecast of Myasthenia Gravis to 2024 Scope: • The Myasthenia Gravis EpiCast Report provides an overview of the risk factors and global trends of myasthenia gravis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of myasthenia gravis, segmented by sex, age, and Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V). • The myasthenia gravis epidemiology report is written and developed by Mastersand PhD-level epidemiologists. • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Epidemiological Forecast of Myasthenia Gravis to 2024 Reasons to Buy: • Develop business strategies by understanding the trends shaping and driving the global myasthenia gravis market. • Quantify patient populations in the global myasthenia gravis market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for myasthenia gravis therapeutics in each of the markets covered. • Identify the percentage of myasthenia gravis prevalent cases by class. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  7. Epidemiological Forecast of Myasthenia Gravis to 2024 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related